Quick Answer
Indivior Pharmaceuticals, Inc. reported Gross Profit of $994.00 million for the year ending 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +3.9% in Gross Profit from 2024 to 2025.
- This data is from Indivior Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $246.00 million | Q2 2024: $220.00 million | Q3 2024: $241.00 million | Q1 2025: $221.00 million | Q2 2025: $250.00 million | Q3 2025: $230.00 million.
- Over the full 5 years of available data (2021 to 2025), Indivior Pharmaceuticals, Inc.'s Gross Profit has grown by 49.7%.
- Historical annual values: Fiscal year 2025: $994.00 million | Fiscal year 2024: $957.00 million | Fiscal year 2023: $919.00 million | Fiscal year 2022: $749.00 million | Fiscal year 2021: $664.00 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: